News Release

Printer Friendly Version View printer-friendly version << Back
April 2, 2003 at 4:01 AM EST

Quidel QuickVue Influenza Test Offers 10-Minute Test Results to Evaluate Respiratory Symptoms

SAN DIEGO, Calif.--(BUSINESS WIRE)--April 2, 2003--Quidel Corporation (Nasdaq:QDEL), a leading provider of rapid point-of-care (POC) diagnostic tests, provides physicians the CLIA-waived, QuickVue(R) Influenza test to distinguish the symptoms of flu from those of other respiratory illnesses that mimic flu-like symptoms. The QuickVue(R) Influenza test provides fast and accurate test results at the point-of-care, to assist the physician in determining the correct diagnosis and begin appropriate treatment. Given the recent anxiety about acute respiratory illness, some patients may actually take solace in knowing they have the flu.

Access to rapid flu test results may be most important in those areas of the country where the Centers for Disease Control and Prevention (CDC) report higher prevalence of influenza this month. The CDC also indicates that personal hygiene and hand washing is the most important measure in preventing the spread of the infection.

Influenza, commonly referred to as the flu, is a serious disease and can lead to serious complications such as pneumonia and heart failure, as well as making an existing chronic disease worse. If left undetected and untreated, influenza can lead to avoidable prolonged illness and possibly even result in unnecessary death. According to the CDC, in the United States, epidemics of influenza are responsible for an average of approximately 36,000 deaths per year and 114,000 hospitalizations per year as a result of influenza.(1) Rates of infection are highest among children. Persons aged 65+ years, as well as persons of any age with chronic medical conditions, and very young children are most likely to get complications from influenza.

"Early diagnosis is critical to the proper treatment of potentially serious respiratory infections, including influenza. The sooner a physician can determine the cause of symptoms, the sooner the patient can receive targeted treatment or continue down the appropriate diagnostic path," said Michael Gerber, MD, Children's Hospital Medical Center of Cincinnati, Division of Infectious Disease. According to S. Wayne Kay, president and chief executive officer of Quidel, "The healthcare industry -- and specifically, hospitals nationwide -- are incorporating a new standard of care to test and treat patients for common but critical everyday medical conditions, such as influenza, in order to prevent potential complications, hospitalizations, and deaths from the virus."

Quidel's QuickVue Influenza test takes approximately 30 seconds of hands-on time, with results in 10 minutes or less. Depending on the type of test and sample taken (nasal swab or nasal wash), the tests are 96-99% accurate. Quidel provides additional information at www.quidel.com. By clicking on the map entitled "Flu Surveillance," information can be obtained on influenza, influenza testing and pathogens ranging from the more common to the very rare, which can cause flu-like symptoms. It provides good information in an easy to read "Frequently Asked Questions" format. The site also contains informational links to federal public health agencies like the CDC and FDA as well as a link to the AMA's "disaster preparedness" site.

    (1) www.cdc.gov/ncidod/diseases/flu/fluinfo.htm

    About Quidel

Quidel Corporation, a worldwide company helping women and their families live healthy lives, discovers, develops, manufactures and markets rapid point-of-care diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions associated with women's health in areas such as reproduction and diseases of the elderly. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, Strep throat, H. pylori infection, chlamydia, infectious mononucleosis and infectious vaginitis. Quidel's products are sold to healthcare professionals for use in physician offices, clinical laboratories and pharmacies, and to consumers through organizations that provide private label, store brand products. These tests provide diagnostic information that enables rapid treatment and improves health outcomes, lowers costs and increases patient satisfaction. For more information, please visit Quidel's Web site at www.quidel.com.

This press release contains forward-looking statements within the meaning of the federal securities laws that involve material risk and uncertainties. Many possible events or factors could affect our future financial results and performance, such that our actual results and performance may differ materially. As such, no forward-looking statement can be guaranteed. Differences in operating results may arise as a result of a number of factors including, without limitation, seasonality, adverse changes in the competitive and economic conditions in domestic and international markets, actions of our major distributors, manufacturing and production delays or difficulties, adverse actions or delays in product reviews by the FDA and the lower acceptance of our new products than forecast. Forward-looking statements typically are identified by the use of terms such as "may," "will," "should," "might," "expect," "anticipate," "estimate" and similar words, although some forward-looking statements are expressed differently. The risks described under "Risk Factors" and in other sections of our Form 10-K for year ended December 31, 2001, and in other reports and registration statements that we file with the Securities and Exchange Commission from time to time should be carefully considered. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this presentation. We undertake no obligation to publicly release the results of any revision of the forward-looking statements.

    CONTACT: Quidel Corporation
             Paul E. Landers, 858/552-7962
             Lippert/Heilshorn & Associates
             Ina McGuinness (imcguinness@lhai.com)
             Bruce Voss (bvoss@lhai.com)

    SOURCE: Quidel Corporation